Published in Vaccine Weekly, January 4th, 2006
Under the study, some two dozen patients suffering from advanced stages of renal cell cancer will be treated in six locations in Germany, the United Kingdom and Switzerland. "With this study, we will be determining the immunoefficacy and compatibility of our new vaccine, thus laying the groundwork for a more far-reaching phase II study," said immatics chief medical officer Jurgen Frisch.
CSO Harpreet Singh stressed the short preclinical study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly